Company intelligence / Profile preview

Activartis Biotech GmbH

Vienna, Vienna, Austriapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

AV0113 has shown promising trends in glioblastoma trials with good tolerability. The therapy uses dendritic cells combined with bacterial danger signals (lipopolysaccharides) and patient's tumor antigens to activate the immune system against cancer. Phase I studies included over 100 patients with different cancer indications.

Therapeutic areas: Oncology
Modalities: Dendritic cell-based immunotherapy
Industry: Biotech

Partnerships

NeoTX Therapeutics Ltd (mentioned in search results but may be referring to a different company)

Beyond the preview

Go deeper on Activartis Biotech GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Activartis Biotech GmbH.

Explore the full profile